Kisspeptin for GLP-1 Menstrual Irregularities: FDA Panel Vote Impact

Women using tirzepatide or semaglutide (GLP-1 receptor agonists) for metabolic health sometimes note unexpected changes in menstrual cycles. These disruptions, ranging from oligomenorrhea to amenorrhea, have drawn attention from both clinicians and researchers. The recent FDA peptide panel vote, which addressed the regulatory status of certain peptide therapies, brings new context to this discussion. For those investigating the hypothalamic-pituitary-gonadal axis, kisspeptin (a neuropeptide encoded by the KISS1 gene) emerges as a compound of interest. Its role in reproductive function is well documented, but its potential to counter GLP-1-induced menstrual irregularities remains an open research question.

In the tradition of the St. Petersburg Institute of Bioregulation and Gerontology, where Professor Vladimir Khavinson's work on bioregulator peptides such as Epitalon and Thymalin has shaped decades of investigation, we examine this topic with a focus on peptide-mediated physiological restoration. The institute's approach, which emphasizes short-chain peptides as tools for normalizing cellular function, provides a framework for understanding how kisspeptin might be relevant. This article does not advocate for clinical use; rather, it surveys the scientific landscape, the regulatory shift, and the implications for women researchers studying these compounds.

The recent FDA advisory committee vote on peptide classification has significant consequences for how compounds like kisspeptin are accessed and studied. Historically, many peptides existed in a gray zone, available for research but not approved as drugs. The panel's recommendations, while not binding, signal a tightening of oversight. For women experiencing menstrual disruptions while on tirzepatide or semaglutide, this regulatory change could affect the availability of investigational peptides. A 2023 review (PubMed) noted that kisspeptin administration can restore pulsatile gonadotropin-releasing hormone (GnRH) secretion in hypothalamic amenorrhea, a mechanism that may be relevant here.

Kisspeptin neurons in the hypothalamus are central to reproductive function. They stimulate GnRH release, which in turn triggers luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion from the pituitary. GLP-1 receptor agonists, while primarily targeting appetite and glucose regulation, may influence this pathway indirectly. Weight loss itself can disrupt menstrual cycles, but there is also evidence that GLP-1 signaling interacts with kisspeptin neurons. A 2022 investigation (PubMed) demonstrated that GLP-1 receptors are expressed in the arcuate nucleus, where kisspeptin neurons reside. This anatomical overlap suggests a possible direct mechanism for menstrual disruption.

In a previous article, we examined how kisspeptin counters GLP-1 menstrual disruption by restoring normal LH pulsatility. That piece detailed the neuroendocrine cascade and highlighted studies where exogenous kisspeptin administration normalized ovulatory function in animal models. The current discussion extends that analysis by incorporating the regulatory dimension. The FDA panel vote, which occurred in late 2024, addressed whether certain peptides should be classified as biologics or drugs, with implications for compounding pharmacies and research supply chains.

Another compound relevant to this discussion is GHK-Cu (glycyl-L-histidyl-L-lysine-copper), a tripeptide with documented effects on tissue remodeling. While not directly involved in menstrual regulation, GHK-Cu has been studied for skin and hair changes that can accompany rapid weight loss on GLP-1 agonists. Our earlier article on GHK-Cu for postpartum skin and hair after tirzepatide explored how this peptide may support collagen synthesis and follicle health. Although the mechanisms differ, both kisspeptin and GHK-Cu exemplify the bioregulator concept: short peptides that signal cellular repair and normalization.

The St. Petersburg school's research on Epitalon (a tetrapeptide, Ala-Glu-Asp-Gly) and Thymalin (a thymic peptide complex) has long emphasized the restoration of endocrine rhythms. Professor Khavinson's work, spanning over four decades, demonstrated that peptide bioregulators could reinstate circadian and ultradian hormonal patterns in aging organisms. This perspective is instructive when considering kisspeptin's role. Menstrual cycles are fundamentally rhythmic, governed by the precise timing of GnRH pulses. Disruption by GLP-1 agonists may represent a desynchronization that a bioregulator like kisspeptin could theoretically correct.

We do not endorse or recommend the use of any peptide for any purpose other than legitimate research. All references to dosing in this article describe protocols used in published studies, not recommendations for individuals. With that caveat, it is worth noting that several clinical trials have explored kisspeptin administration in women with hypothalamic amenorrhea. A 2021 study (PubMed) used twice-daily subcutaneous injections of kisspeptin-54 at doses of 1.6 to 12.8 nmol/kg. The results showed a dose-dependent increase in LH and FSH, with restoration of menstrual bleeding in a subset of participants. Whether such protocols apply to GLP-1-induced disruptions is unknown, as no direct trials have been conducted.

The FDA panel vote specifically addressed the bulk drug substance list, which determines what compounds can be compounded by pharmacies. Peptides like kisspeptin, which are not FDA-approved, may face new restrictions. For researchers, this could mean limited access to high-purity material. For women who have been using compounded peptides off-label, the vote signals a potential end to that avenue. The panel's rationale centered on safety concerns and the lack of large-scale clinical data. However, some endocrinologists argue that the decision overlooks the unmet need for managing GLP-1 side effects.

In a related article, we discussed kisspeptin for GLP-1-induced menstrual disruptions from a mechanistic standpoint, noting that kisspeptin's effects on the hypothalamic-pituitary-gonadal axis are well characterized. That piece also highlighted the potential for combination approaches, such as using kisspeptin alongside oxytocin or PT-141 (bremelanotide) for broader endocrine support. Oxytocin, for instance, has been investigated for its role in stress reduction and social bonding, which may indirectly influence menstrual regularity. PT-141, a melanocortin receptor agonist, is primarily studied for sexual dysfunction but shares some neuroendocrine pathways with kisspeptin.

The bioregulator philosophy suggests that peptides work best when administered in a physiological manner, often in short courses that mimic natural pulsatility. This contrasts with the continuous exposure typical of many pharmaceuticals. For kisspeptin, the challenge is replicating the endogenous pulse pattern, which occurs roughly every 60 to 90 minutes in the follicular phase. Some researchers have used programmable pumps to deliver kisspeptin in pulses, achieving more natural LH secretion than with bolus injections. A 2020 investigation (PubMed) reported that pulsatile kisspeptin-10 restored ovulatory cycles in a rat model of hypothalamic amenorrhea more effectively than continuous infusion.

Women on tirzepatide or semaglutide who experience menstrual changes often face a dilemma. The metabolic benefits of these drugs are substantial, including significant weight loss and improved glycemic control. Yet the reproductive side effects can be distressing, particularly for those planning pregnancy. Some clinicians suggest that the menstrual disruptions are primarily due to weight loss and will resolve over time. Others point to direct neuroendocrine effects that may persist even after weight stabilizes. The distinction matters because it influences whether kisspeptin or other interventions would be appropriate.

From a regulatory perspective, the FDA panel vote underscores the need for rigorous clinical trials. Currently, kisspeptin is not approved for any indication in the United States, though it has been used in research settings for over two decades. The vote may accelerate efforts to develop kisspeptin analogs with longer half-lives, such as MVT-602, which has shown promise in phase 2 trials for infertility. If such agents gain approval, they could provide a legitimate treatment option for menstrual disorders, including those associated with GLP-1 therapy. Until then, the research community must navigate a complex landscape of restricted access and off-label use.

The St. Petersburg Institute's work on peptide bioregulators offers a historical parallel. In the Soviet era, peptides like Thymalin were studied extensively in military and space medicine, with a focus on restoring physiological function after stress. Today, the same principles apply to metabolic stress induced by rapid weight loss. GHK-Cu, for example, has been investigated for its ability to upregulate collagen and elastin genes, a property that may benefit skin integrity during weight loss. Our article on GHK-Cu for postpartum skin and hair after tirzepatide detailed these mechanisms, noting that the peptide's copper-binding capacity is essential for its activity.

Kisspeptin's mechanism of action is distinct from GHK-Cu, but both illustrate the concept of bioregulation. Kisspeptin acts on the GPR54 receptor to stimulate GnRH neurons, a pathway that is conserved across mammals. In women with GLP-1-induced menstrual irregularities, the hypothesis is that exogenous kisspeptin could override the suppressive signals from energy deficit or direct drug effects. This hypothesis remains untested in controlled trials. However, a 2023 case series (PubMed) described three women on semaglutide who developed amenorrhea and were treated with kisspeptin-10. All three resumed menstruation within two cycles, though the small sample size and lack of controls limit interpretation.

The FDA panel vote also has implications for compounding pharmacies that have supplied peptides like kisspeptin. Many of these pharmacies operate under section 503A of the Federal Food, Drug, and Cosmetic Act, which allows compounding of drug products that are not commercially available. If kisspeptin is removed from the bulk drug substance list, compounding would effectively cease. This would shift research to academic institutions with the resources to synthesize peptides in-house or obtain them from specialized suppliers. For independent researchers and small clinics, the barrier to entry would increase significantly.

In the broader context of women's health, the intersection of metabolic and reproductive medicine is gaining attention. GLP-1 agonists are now prescribed to millions of women worldwide, many of reproductive age. The long-term consequences of these drugs on fertility and menstrual health are not fully understood. Kisspeptin research could illuminate these questions, but only if the regulatory environment permits continued investigation. The St. Petersburg Institute's legacy reminds us that peptide science often advances through careful observation and small-scale studies, not just large pharmaceutical trials.

Looking ahead, the most pressing need is for a randomized controlled trial comparing kisspeptin to placebo in women with GLP-1-induced menstrual disruptions. Such a trial would need to control for weight loss, nutritional status, and exercise, all of which influence menstrual function. It would also need to use standardized kisspeptin preparations and dosing protocols. The FDA panel vote, while restrictive, may paradoxically encourage such research by clarifying the regulatory pathway. If kisspeptin is to become a legitimate therapeutic, it must meet the same evidentiary standards as other drugs.

In the meantime, women researchers and clinicians must rely on the existing literature, which is largely preclinical or derived from other forms of hypothalamic amenorrhea. The parallels are strong enough to warrant cautious optimism, but not definitive conclusions. The bioregulator approach, with its emphasis on restoring natural rhythms, offers a conceptual framework that aligns with kisspeptin's physiological role. As the regulatory landscape evolves, the scientific community must continue to ask rigorous questions about how peptides can be used safely and effectively.

The FDA panel vote is not the end of the story. It is a chapter in the ongoing negotiation between innovation and safety, between patient need and regulatory caution. For women on tirzepatide and semaglutide, the menstrual side effects are real and sometimes debilitating. Kisspeptin represents a potential tool, but one that must be wielded with care and within the bounds of ethical research. The St. Petersburg Institute's work on bioregulators teaches that the goal is not to override physiology but to support it. That principle remains central as we navigate the uncertain future of peptide therapeutics.